GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Valuation Rank

MaxCyte (LSE:MXCT) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is MaxCyte Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

MaxCyte Valuation Rank Related Terms

Thank you for viewing the detailed overview of MaxCyte's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

MaxCyte (LSE:MXCT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Valuation Rank
Comparable Companies
LSE:NIOX LSE:EKF LSE:CREO LSE:BELL LSE:IUG LSE:IHC LSE:POLX LSE:SUN LSE:MHC LSE:DEMG ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
MXCT:USA MYE0:Germany
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
Website
https://www.maxcyte.com
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.